The processes required for C> manufacture are wholly new and extremely complex. As production and delivery of these new therapies to patients are still nascent, biopharmaceutical companies will need to harness new technological advances and innovate continuously in the manufacturing process.
Large capital investments in the industry are likely to bring breakthroughs in the coming years that will standardise processes, simplify delivery logistics, boost efficiency, and increase competition.
Read the full report
Our Thought Leadership team produces original, evidence-based research made accessible to decision-makers and opinion leaders. Principals for this project included:
Oxford Economics’ team is expert at applying advanced economic tools that provide valuable insights into today’s most pressing business, financial, and policy issues.
To find out more about our capabilities, contact:
020 3910 8000
+1 646 503 3048
+852 3974 8841
Delivering Value: The Economic Impact of the Civil Nuclear Industry
The study suggests the civil nuclear industry supports a £16.1 billion contribution to UK GDP, 211,500 jobs, and £7.1 billion in tax revenues. 24% occurs in the North West and 16% in the South West.Find Out More
Innovation Index: Are You Prepared to Shift from Survival to Growth?
Oxford Economics and NTT Data fielded a survey of 1,000 North American business and IT executives in 2022 to uncover future strategies to mitigate disruption.Find Out More
Reinventing for growth in a changing media landscape
Oxford Economics partnered with Accenture to survey 6,000 consumers around the world about their media and entertainment habits, experiences, and preferences.Find Out More